Background. Myocardial ischemial reperfusion represents a clinically relevant problem associated with thrombolysis, angioplasty, and coronary bypass surgery. Injury of myocardium due to ischemial reperfusion includes cardiac contractile dysfunction, arrhythmias, and irreversible myocytes damage. These changes are considered to be the consequence of imbalance between the formation of oxidants and the availability of endogenous antioxidants in the heart. Objective. This study was undertaken to investigate the potential role of Simvastatin in the amelioration of myocardial I/R injury induced by ligation of coronary artery in a rat model. Materials and Methods. Adult male Swiss Albino rats were randomized into 4 equal groups. Group (1): sham group: rats underwent the same anesthetic and surgical procedures as those in the control group except ligation of LAD coronary artery, group (2): control group: rats were subjected to regional ischemia for 25？min and reperfusion for 2 hours by ligation of LAD coronary artery, group (3): control vehicle group: rats received vehicle of Simvastatin (normal saline) via IP injection and were subjected to regional ischemia for 25？min and reperfusion for 2 hours by ligation of LAD coronary artery, group (4): Simvastatin treated group: rats were pretreated with Simvastatin 1？mg/kg i.p. 1？hr before ligation of LAD coronary artery. At the end of experiment (2？hr of reperfusion), blood samples were collected from the heart for the measurement of plasma level of cardiac troponin I (cTnI). After that the heart was harvested and divided into 3 parts; one part was used for measurement of apoptosis, another part was homogenized for the measurement of tissue tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1α, and the last part for histopathology study. Results. Compared with the sham group, levels of myocardial TNF-α and IL-1β, IL-6, MCP-1, and MIP-1α and plasma cTnI were increased ( ). Histologically, all rats in control group showed significant ( ) cardiac injury. Furthermore, all rats in control group showed significant ( ) apoptosis. Simvastatin significantly counteracted the increase in myocardium level of TNF-α, IL-1B, IL-6, MCP-1 and MIP-1α, plasma cTnI, and apoptosis ( ). Histological analysis revealed that Simvastatin markedly reduced ( ) the severity of heart injury in the rats that underwent LAD ligation procedure. Conclusions. The results of the present study reveal that Simvastatin may ameliorate myocardial I/R injury in rats
References
[1]
B. Dorweiler, D. Pruefer, T. B. Andrasi et al., “Ischemia-reperfusion injury: pathophysiology and clinical implications,” European Journal of Trauma and Emergency Surgery, vol. 33, no. 6, pp. 600–612, 2007.
[2]
A. Anselmi, A. Abbate, F. Girola et al., “Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence,” European Journal of Cardio-Thoracic Surgery, vol. 25, no. 3, pp. 304–311, 2004.
[3]
J. E. Jordan, Z.-Q. Zhao, and J. Vinten-Johansen, “The role of neutrophils in myocardial ischemia-reperfusion injury,” Cardiovascular Research, vol. 43, no. 4, pp. 860–878, 1999.
[4]
H. K. Eltzschig and C. D. Collard, “Vascular ischaemia and reperfusion injury,” British Medical Bulletin, vol. 70, pp. 71–86, 2004.
[5]
J. Lutz, K. Thürmel, and U. Heemann, “Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation,” Journal of Inflammation, vol. 7, article 27, 2010.
[6]
Z.-Q. Zhao, M. Nakamura, N.-P. Wang et al., “Reperfusion induces myocardial apoptotic cell death,” Cardiovascular Research, vol. 45, no. 3, pp. 651–660, 2000.
[7]
S. H. Kaufmann and M. O. Hengartner, “Programmed cell death: alive and well in the new millennium,” Trends in Cell Biology, vol. 11, no. 12, pp. 526–534, 2001.
[8]
S. Nagata, “Apoptotic DNA fragmentation,” Experimental Cell Research, vol. 256, no. 1, pp. 12–18, 2000.
[9]
J. Davignon, “Beneficial cardiovascular pleiotropic effects of statins,” Circulation, vol. 109, no. 23, supplement 1, pp. III39–III43, 2004.
[10]
B. V. Naidu, S. M. Woolley, A. S. Farivar, R. Thomas, C. Fraga, and M. S. Mulligan, “Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion,” The Journal of Thoracic and Cardiovascular Surgery, vol. 126, no. 2, pp. 482–489, 2003.
[11]
A. Undas, M. Celińska-L？wenhoff, M. Kaczor, and J. Musial, “New nonlipid effects of statins and their clinical relevance in cardiovascular disease,” Thrombosis and Haemostasis, vol. 91, no. 6, pp. 1065–1077, 2004.
[12]
T. Rajtík, S. Carnická, A. Szobi, L. Mesáro？ová, M. Má？u？, P. Svec, et al., “Pleiotropic effects of simvastatin are associated with mitigation of apoptotic component of cell death upon lethal myocardial reperfusion-induced injury,” Physiological Research, vol. 61, supplement 2, pp. S33–S41, 2012.
[13]
Y. Wu, X. Yin, C. Wijaya, M.-H. Huang, and B. K. McConnell, “Acute myocardial infarction in rats,” Journal of Visualized Experiments, no. 48, Article ID e2464, 2011.
[14]
D. Wiedemann, S. Schneeberger, P. Friedl et al., “The fibrin-derived peptide Bβ15–42 significantly attenuates ischemia-reperfusion injury in a cardiac transplant model,” Transplantation, vol. 89, no. 7, pp. 824–829, 2010.
[15]
J.-W. Ding, X.-H. Tong, J. Yang et al., “Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart,” Journal of Korean Medical Science, vol. 25, no. 11, pp. 1609–1615, 2010.
[16]
N. S. Wayman, B. L. Ellis, and C. Thiemermann, “Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat,” Medical Science Monitor, vol. 9, no. 5, pp. BR155–BR159, 2003.
[17]
B. Zingarelli, A. L. Salzman, and C. Szabó, “Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury,” Circulation Research, vol. 83, no. 1, pp. 85–94, 1998.
[18]
M. R. Gholami, F. Abolhassani, P. Pasbakhsh et al., “The effects of simvastatin on ischemia-reperfusion injury of sciatic nerve in adult rats,” European Journal of Pharmacology, vol. 590, no. 1–3, pp. 111–114, 2008.
[19]
A. M. Lefer, B. Campbell, Y.-K. Shin, R. Scalia, R. Hayward, and D. J. Lefer, “Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts,” Circulation, vol. 100, no. 2, pp. 178–184, 1999.
[20]
M. Zhang, Y. J. Xu, H. K. Saini, B. Turan, P. P. Liu, and N. S. Dhalla, “Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfusedheart,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 2, pp. H832–H839, 2005.
[21]
M. Granado, N. Fernández, L. Monge et al., “Effects of coronary ischemia-reperfusion in a rat model of early overnutrition. Role of angiotensin receptors,” PLoS ONE, vol. 8, no. 2, Article ID e54984, 2013.
[22]
R. F. Tuma and S. Steffens, “Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury,” Current Pharmaceutical Biotechnology, vol. 13, no. 1, pp. 46–58, 2012.
[23]
S. Steffens, F. Montecucco, and F. Mach, “The inflammatoryresponse as a target to reducemyocardial ischaemia and reperfusion injury,” Thrombosis and Haemostasis, vol. 102, no. 2, pp. 240–247, 2009.
[24]
J. Zhang, X. Cheng, Y.-H. Liao et al., “Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction,” Cardiovascular Drugs and Therapy, vol. 19, no. 1, pp. 13–21, 2005.
[25]
F.-Q. Sheng, R. Xu, L.-X. Cheng et al., “In rats with myocardial infarction, interference by simvastatin with the TLR4 signal pathway attenuates ventricular remodelling,” Acta Cardiologica, vol. 64, no. 6, pp. 779–785, 2009.
[26]
B. Hajipour, M. H. Somi, F. Saberifar et al., “Simvastatin attenuates intestinal ischaemia/reperfusion-induced injury in rat,” Folia Morphologica, vol. 68, no. 3, pp. 156–162, 2009.
[27]
A. C. B. Dantas, F. F. D. A. Batista Jr., L. F. Macedo, M. N. C. Mendes, í. M. Azevedo, and A. C. Medeiros, “Protective effect of simvastatin in the cyclophosphamide-induced hemohrragic cystitis in rats,” Acta Cirurgica Brasileira, vol. 25, no. 1, pp. 43–46, 2010.
[28]
N. R. Veillard, V. Braunersreuther, C. Arnaud et al., “Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages,” Atherosclerosis, vol. 188, no. 1, pp. 51–58, 2006.
[29]
M. Bruegel, D. Teupser, I. Haffner, M. Mueller, and J. Thiery, “Statins reduce macrophage inflammatory protein-1α expression in human activated monocytes,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 12, pp. 1144–1149, 2006.
[30]
H. Cakmak, M. Basar, Y. Seval-Celik, et al., “Statins inhibit monocyte chemotactic protein 1 expression in endometriosis,” Reproductive Sciences, vol. 19, no. 6, pp. 572–579, 2012.
[31]
H.-L. Yang, X.-P. Huang, L. Sun, et al., “Effects of simvastatin on cardiac function and serum cardiac troponin I in patients with chronic heart failure,” Modern Medicine & Health 2009-09-005.
[32]
M. A. Almansob, B. Xu, L. Zhou et al., “Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2304–2313, 2012.
[33]
J. Veselka, S. Procházková, R. Duchonová, I. Homolová, D. Tesar, and K. A. Bybee, “Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention,” Heart and Vessels, vol. 21, no. 3, pp. 146–151, 2006.
[34]
N. A. Abd Elbaky, A. A. Ali, and R. A. Ahmed, “Cardioprotective effect of simvastatin on doxorubicininduced oxidative cardiotoxicity in rats,” Journal of Basic and Applied Sciences, vol. 6, no. 1, pp. 29–38, 2010.
[35]
S. A. Hamid, H. S. Bower, and G. F. Baxter, “Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium,” American Journal of Physiology–Heart and Circulatory Physiology, vol. 292, no. 6, pp. H2598–H2606, 2007.
[36]
N. Slijper, I. Sukhotnik, E. Chemodanov et al., “Effect of simvastatin on intestinal recovery following gut ischemia-reperfusion injury in a rat,” Pediatric Surgery International, vol. 26, no. 1, pp. 105–110, 2010.
[37]
F. Dibazar, B. Hajipour, M. M. Hosseinian, M. R. Hemmati, and A. Ghandiha, “Simvastatin decreases hepatic ischaemia/reperfusion-induced liver and lung injury in rats,” Folia Morphologica, vol. 67, no. 4, pp. 231–235, 2008.
[38]
M. L. Ko, C. F. Chen, P. H. Peng, and Y. H. Peng, “Simvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina,” Experimental Eye Research, vol. 93, no. 5, pp. 580–585, 2011.
